Reported Earlier, Viridian Therapeutics Prices Upsized $350M Concurrent Offerings Of $225M 1.75% Convertible Notes Due 2032 And 7,352,942 Common Shares At $17.00 Per Share

Benzinga Newsdesk www.benzinga.com Neutral 71.3%

Neg 0% Neu 71.3% Pos 0%

Comments

No comments yet. Be the first!